{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T13:38:24.255906+00:00","company":{"ticker":"NUTX","cik":1479681,"company_name":"Nutex Health Inc."},"pagination":{"limit":100,"returned":6,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"008cb286f23ed7238d4674f939f7e1d41d498746","cik":1479681,"ticker":"NUTX","company_name":"Nutex Health Inc.","filed_at":"2026-04-30T23:59:59+00:00","payload":{"eps_text":"$6.52","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$46.8 million","period_text":"first quarter ending March 31, 2026","report_date":"2026-04-30","result_type":"reported_results","revenue_text":"$216.5 million"},"claim":"Nutex Health Inc. reported first quarter ending March 31, 2026 results: revenue $216.5 million, net income $46.8 million, EPS $6.52.","evidence_excerpt":"division ), and a primary care-centric, risk-bearing physician network. Financial highlights for the three months ended March 31, 2026 : • Total revenue increased 2.2% to $216.5 million compared to $211.8 million for the same period in 2025, driven by 1.8% growth in hospital division revenue to $207.6 million from $203.9 million, while revenue at same hospitals,","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-028852","anchor_url":"https://secwatch.observer/filing/0001628280-26-028852#claim-008cb286f23ed7238d4674f939f7e1d41d498746","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1479681/000162828026028852/0001628280-26-028852-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"4c889287914975bb6a10f2793bfa2369cc2ce657","cik":1479681,"ticker":"NUTX","company_name":"Nutex Health Inc.","filed_at":"2025-10-20T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2025-12-12","deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-10-16","notice_type":"extension_granted","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5250(c)(1)","reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"Nutex Health Inc. received a nasdaq extension granted notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"October 16, 2025. In the event the Company is not able to file the June 30, 2025 Form 10-Q with the SEC on or before December 12, 2025, the staff of Nasdaq will issue a delisting notice, which the Company may appeal to a Nasdaq Hearings Panel.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001479681-25-000085","anchor_url":"https://secwatch.observer/filing/0001479681-25-000085#claim-4c889287914975bb6a10f2793bfa2369cc2ce657","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1479681/000147968125000085/0001479681-25-000085-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"1fe827f58c0a3d4e208fb01d1f8f3d06f8389e43","cik":1479681,"ticker":"NUTX","company_name":"Nutex Health Inc.","filed_at":"2025-10-20T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2025-12-12","deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-08-20","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"Nutex Health Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"August 20, 2025, the Company received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that due to the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “June 30, 2025 Form 10-Q”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires the timely filing of all required periodic reports with the SEC. On October 15","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001479681-25-000085","anchor_url":"https://secwatch.observer/filing/0001479681-25-000085#claim-1fe827f58c0a3d4e208fb01d1f8f3d06f8389e43","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1479681/000147968125000085/0001479681-25-000085-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"f2ef058ed7e22411e12bca1307c644553e7dc548","cik":1479681,"ticker":"NUTX","company_name":"Nutex Health Inc.","filed_at":"2025-08-21T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-08-20","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"Nutex Health Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"August 20, 2025, the Company received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that due to the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “June 30, 2025 Form 10-Q”), with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires the timely filing of all required periodic reports with the SEC. Under Nasdaq r","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001479681-25-000068","anchor_url":"https://secwatch.observer/filing/0001479681-25-000068#claim-f2ef058ed7e22411e12bca1307c644553e7dc548","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1479681/000147968125000068/0001479681-25-000068-index.htm"},{"fact_type":"auditor_change","fact_key":"9bf025c48e5bb08d29acc5e22e2fdfac02cd05b8","cik":1479681,"ticker":"NUTX","company_name":"Nutex Health Inc.","filed_at":"2025-08-21T23:59:59+00:00","payload":{"action":"non_reliance","auditor_name":null,"disagreement_text":null,"effective_date":"2025-08-20","item_codes_triggered":["4.02"],"non_reliance_signal":"restatement","successor_auditor_name":null},"claim":"Nutex Health Inc. reported that prior financial statements should not be relied upon.","evidence_excerpt":"ber 31, 2024 (the “Original Form 10-K”) (collectively, the “Previously Issued Financial Statements”) treated non-cash obligations related to under-construction and ramping hospitals as equity rather than liabilities and should be restated. The Company does not anticipate any material changes for the first three quarters of interim financial statements for fiscal year 2024. The Company expects that any adjustments related to the treatment of these obligations will be non-cash in nature and have no effect on key financial statement line items such as its revenue, gross profit, liquidity, working capital, short-term and long-term debt, operating cash flow, adjusted EBITDA or number of patient visits as of and for the periods presented therein to be reflected in the fourth quarter of 2024. Accordingly, investors and all other persons should no longer rely upon the Previously Issued Financial","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001479681-25-000068","anchor_url":"https://secwatch.observer/filing/0001479681-25-000068#claim-9bf025c48e5bb08d29acc5e22e2fdfac02cd05b8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1479681/000147968125000068/0001479681-25-000068-index.htm"},{"fact_type":"earnings_release","fact_key":"807fc32a4f84221fe265e49d4e2a211235c34f58","cik":1479681,"ticker":"NUTX","company_name":"Nutex Health Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss attributable to Nutex Health Inc. of $0.4 million","period_text":"first quarter 2024","report_date":"2024-05-08","result_type":"reported_results","revenue_text":"$67.5 million"},"claim":"Nutex Health Inc. reported first quarter 2024 results: revenue $67.5 million, net income Net loss attributable to Nutex Health Inc. of $0.4 million.","evidence_excerpt":"Total revenue of $67.5 million as compared to total revenue of $56.3 million for the three months ended March 31, 2023, an increase of approximately 20%. Of this revenue growth, mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 6.7% in 2024 compared to 2023. ● Total visits from the Hospital Division were 40,068 for the first quarter 2024 as compared to 33,085 for the first quarter 2023, an increase of 6,983 or 21.1%. Of this visit growth, mature hospitals increased by 5.3% in 2024 compared to 2023. ● Net loss attributable to Nutex Health Inc. of $0.4 million as compared to net loss attributable to Nutex Health Inc. of $5.1 million for the three months ended March 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-24-007416","anchor_url":"https://secwatch.observer/filing/0001558370-24-007416#claim-807fc32a4f84221fe265e49d4e2a211235c34f58","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1479681/000155837024007416/0001558370-24-007416-index.htm"}]}